P. Philippe-Chomette (Chirurgien pédiatre praticien hospitalier) , D. Orbach (Oncologue pédiatre) , H. Brisse (Radiologue) , Y. Aigrain (Professeur des Universités, chirurgien pédiatre) , D. Berrebi , A. El Ghoneimi (Professeur des Universités, chirurgien pédiatre)
{"title":"Rhabdomyosarcomes du sinus urogénital de l'enfant","authors":"P. Philippe-Chomette (Chirurgien pédiatre praticien hospitalier) , D. Orbach (Oncologue pédiatre) , H. Brisse (Radiologue) , Y. Aigrain (Professeur des Universités, chirurgien pédiatre) , D. Berrebi , A. El Ghoneimi (Professeur des Universités, chirurgien pédiatre)","doi":"10.1016/j.anuro.2006.08.002","DOIUrl":null,"url":null,"abstract":"<div><p>Genitourinary rhabdomyosarcoma (RMS) accounts for approximately 25% of all rhabdomyosarcomas. Management of RMS at this site has changed during the last 5 consecutive Intergroup Rhabdomyosarcoma (IRS) trials, with increasing emphasis of bladder and vaginal conservation. As more effective treatment regimens has improved survival, surgical approaches have evolved to less aggressive management of the primary tumour to improve conservation. Various combinations of chemotherapy, irradiation and surgery have resulted in a decreased late sequelae in the group of patients with sarcoma arising in the genitourinary tract.</p></div>","PeriodicalId":50783,"journal":{"name":"Annales D Urologie","volume":"40 5","pages":"Pages 280-296"},"PeriodicalIF":0.0000,"publicationDate":"2006-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.anuro.2006.08.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales D Urologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003440106000933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Genitourinary rhabdomyosarcoma (RMS) accounts for approximately 25% of all rhabdomyosarcomas. Management of RMS at this site has changed during the last 5 consecutive Intergroup Rhabdomyosarcoma (IRS) trials, with increasing emphasis of bladder and vaginal conservation. As more effective treatment regimens has improved survival, surgical approaches have evolved to less aggressive management of the primary tumour to improve conservation. Various combinations of chemotherapy, irradiation and surgery have resulted in a decreased late sequelae in the group of patients with sarcoma arising in the genitourinary tract.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
